Zenon D Konteatis

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Agios Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, Les Laboratoires Servier. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zenon D Konteatis. Retrieved from https://idiyas.com/inventor/zenon-d-konteatis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 93.3

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 46(Granted Patents)

Location History:

Chatham, NJ (US) (2017 - 2024)
Chatham Township, NJ (US) (2024)

Company Filing History:

9 out of 99

Agios Pharmaceuticals, Inc.

patents

5 out of 24

Servier Pharmaceuticals LLC

patents

1 out of 296

Les Laboratoires Servier

patents

Years Active: 2017-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673961 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2026-07-07),

2. 12433895 - Therapeutically active compounds and their methods of use (2025-10-07),

3. 12077534 - Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer (2024-09-03),

4. RE49934 - Inhibitors of cellular metabolic processes (2024-04-23),

5. 11919915 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2024-03-05),

6. 11844758 - Therapeutically active compounds and their methods of use (2023-12-19),

7. 11524960 - Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer (2022-12-13),

8. 11325914 - Inhibitors of cellular metabolic processes (2022-05-10),

9. 10946023 - Therapeutically active compounds and their methods of use (2021-03-16),

10. 10800782 - Inhibitors of cellular metabolic processes (2020-10-13),

11. 10376510 - 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer (2019-08-13),

12. 10329298 - Inhibitors of cellular metabolic processes (2019-06-25),

13. 10172864 - Therapeutically active compounds and their methods of use (2019-01-08),

14. 10028961 - Therapeutically active compounds and their methods of use (2018-07-24),

15. 9579324 - Therapeutically active compounds and their methods of use (2017-02-28),

Title: Zenon D Konteatis: Innovator in Cancer Treatment

Introduction

Zenon D Konteatis is a prominent inventor based in Chatham, NJ (US), known for his significant contributions to the field of cancer treatment. With a total of 14 patents to his name, he has made remarkable strides in developing therapeutically active compounds aimed at combating cancer.

Latest Patents

Konteatis's latest patents include innovative compounds that are useful for treating cancer. One of his notable patents describes compounds that can be administered to a subject in need of cancer treatment. Another patent focuses on aza-heterobicyclic inhibitors of methionine adenosyltransferase isoform 2A (MAT2A), providing pharmaceutical compositions and methods for treating cancers, particularly those associated with the deletion of the gene encoding methylthioadenosine phosphorylase (MTAP).

Career Highlights

Throughout his career, Zenon D Konteatis has worked with leading pharmaceutical companies, including Agios Pharmaceuticals, Inc. and Servier Pharmaceuticals LLC. His work has been instrumental in advancing cancer therapies and improving patient outcomes.

Collaborations

Konteatis has collaborated with notable professionals in the field, including Jeremy Mark Travins and Janeta Popovici-Muller. These collaborations have further enhanced his research and development efforts in cancer treatment.

Conclusion

Zenon D Konteatis is a distinguished inventor whose work in cancer treatment has led to the development of innovative therapeutic compounds. His contributions continue to impact the medical field positively.

Profile summary based on public USPTO records.